35 studies found for:    " July 22, 2009":" August 21, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Unknown  Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)
Condition: HIV Infections
Intervention: Drug: Adaptavir (monomeric DAPTA)
22 Completed
Has Results
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
Conditions: HIV Infections;   Hepatitis C;   HCV Infection
Interventions: Drug: PegIFN-2b;   Drug: RBV;   Drug: Placebo to Boceprevir;   Drug: Boceprevir
23 Completed Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)
Condition: HIV Infections
Interventions: Drug: fosamprenavir/ritonavir;   Drug: olanzapine
24 Unknown  Reducing HIV Risks in African American Teens
Condition: HIV Infections
Intervention: Behavioral: Healthy Futures parent education
25 Completed Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Drug: efavirenz/emtricitabin/tenofovir;   Drug: lopinavir/ritonavir
26 Completed Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women
Condition: HIV Infections
Intervention:
27 Completed
Has Results
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
Conditions: HIV Infections;   Pneumococcal Infections
Interventions: Biological: 13-valent pneumococcal conjugate vaccine;   Procedure: Blood draw
28 Completed Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
Conditions: HIV Infections;   Pneumococcal Infections
Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC);   Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS);   Procedure: Blood draw
29 Completed Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761;   Drug: Lopinavir/ritonavir;   Drug: HAART;   Drug: Placebo
30 Active, not recruiting
Has Results
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572;   Drug: efavirenz
31 Active, not recruiting
Has Results
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572 (Cohort I);   Drug: GSK1349572 (Cohort II)
32 Completed
Has Results
Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
Condition: HIV
Interventions: Drug: Truvada;   Drug: Combivir;   Drug: Trizivir
33 Completed Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Condition: HIV Infections
Intervention:
34 Completed Faster Identification of TB and Evaluation of Drug Resistance in HIV-infected People
Condition: HIV Infections
Intervention:
35 Active, not recruiting Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men
Conditions: Anal Cancer;   Nonneoplastic Condition;   Precancerous Condition
Intervention: Other: Papanicolaou test

Show previous page of results Previous Page (1-20) Studies Shown (21-35) Next Page
Indicates status has not been verified in more than two years